Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression.
Overexpression of epidermal growth factor receptor (EGFR) is correlated with loss of estrogen receptor and poor prognosis in breast cancer. To investigate this phenomenon, we transfected a cytomegalovirus expression vector directing the expression of EGFR into estrogen receptor-positive MCF-7 breast cancer cells and into a clone of MCF-7 cells previously transfected with transforming growth factor alpha. Cells arising from single clones or pooled polyclonal populations maintained in charcoal-stripped calf serum, a medium devoid of estrogen, overexpressed EGFR. Switching these cells to a medium containing fetal calf serum or charcoal-stripped calf serum plus 17 beta-estradiol resulted in the emergence of a population expressing low EGFR levels. Loss of expression was not a consequence of nonspecific repression of the cytomegalovirus promoter, because expression of the fibroblast growth factor (FGF)-4 complementary DNA in a similar vector was not lost in fetal calf serum. While loss of EGFR overexpression in fetal calf serum was seen at both the protein and mRNA levels, Southern blotting shows that this was not due to loss of the transfected gene. Subclones of a cell population with low EGFR expression were capable of increasing expression upon estrogen withdrawal, demonstrating that the changes in EGFR expression were reversible and suggesting a growth advantage conferred by EGFR overexpression under these restrictive growth conditions. Overexpression of EGFR did not result in loss of ER expression. These results suggest a role for overexpression of EGFR in the growth of estrogen receptor-positive breast cancer cells in the absence of estrogen.
Miller
D L
DL
Lombardi Cancer Research Center, Georgetown University Medical Center, Washington, DC 20007.
el-Ashry
D
D
Cheville
A L
AL
Liu
Y
Y
McLeskey
S W
SW
Kern
F G
FG
D000818:Animals; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D002417:Cattle; D002455:Cell Division; D002460:Cell Line; D003470:Culture Media; D003587:Cytomegalovirus; D066246:ErbB Receptors / Q000096:biosynthesis / Q000378:metabolism*; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D051519:Fibroblast Growth Factor 4; D005346:Fibroblast Growth Factors / Q000096:biosynthesis; D015870:Gene Expression / Q000187:drug effects; D005822:Genetic Vectors; D006801:Humans; D011379:Prognosis; D011401:Promoter Regions, Genetic; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis; D011960:Receptors, Estrogen / Q000378:metabolism*; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000378:metabolism; D015183:Restriction Mapping; D014162:Transfection; D014407:Tumor Cells, Cultured
D003470:Culture Media; C496445:FGF4 protein, human; D051519:Fibroblast Growth Factor 4; D011518:Proto-Oncogene Proteins; D011960:Receptors, Estrogen; D011994:Recombinant Proteins; D004958:Estradiol; D005346:Fibroblast Growth Factors; D066246:ErbB Receptors